Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/06/19 15:28:38」(JST)

wiki en

Fosaprepitant (Emend for Injection (US), Ivemend (EU)) is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant.

Fosaprepitant was developed by Merck & Co. and was approved by the United States Food and Drug Administration (FDA) on January 25, 2008^[1] and by the European Medicines Agency (EMA) on January 11 of the same year.^[2]

References

^ "Drugs.com, FDA Approves Emend (fosaprepitant dimeglumine) for Injection, Merck's New Intravenous Therapy, for Use in Combination with Other Antiemetics for Prevention of Nausea and Vomiting Caused by Chemotherapy". Retrieved 2008-03-15.
^ "European Public Assessment Report for Ivemend (from the EMEA website)". Retrieved 2008-03-15.

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by expanding it.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 制吐剤の特性 characteristics of antiemetic drugs
2. 化学療法誘発性悪心および嘔吐の予防および治療 prevention and treatment of chemotherapy induced nausea and vomiting
3. 化学療法誘発性悪心および嘔吐の病態生理および予測 pathophysiology and prediction of chemotherapy induced nausea and vomiting
4. 麻酔後ケア病棟における合併症発生の概要 overview of complications occurring in the post anesthesia care unit

English Journal

Fosaprepitant for the prevention of nausea and vomiting in patients receiving BEAM or high-dose melphalan before autologous hematopoietic stem cell transplant.

Clark SM1, Clemmons AB2, Schaack L3, Garren J4, DeRemer DL2, Kota VK5.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.J Oncol Pharm Pract.2015 May 7. pii: 1078155215585190. [Epub ahead of print]
PURPOSE: To assess the impact of single-dose fosaprepitant on nausea and emesis after BEAM and high-dose melphalan conditioning regimens for autologous hematopoietic stem cell transplantation.METHODS: In a single-center cohort study patients receiving melphalan containing hematopoietic stem cell tra
PMID 25956421

Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled phase 3 trial.

Nishimura J1, Satoh T2, Fukunaga M3, Takemoto H3, Nakata K3, Ide Y4, Fukuzaki T5, Kudo T2, Miyake Y6, Yasui M7, Morita S8, Sakai D2, Uemura M9, Hata T9, Takemasa I9, Mizushima T9, Ohno Y10, Yamamoto H9, Sekimoto M11, Nezu R12, Doki Y9, Mori M9; Multi-center Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO).
European journal of cancer (Oxford, England : 1990).Eur J Cancer.2015 Apr 24. pii: S0959-8049(15)00291-9. doi: 10.1016/j.ejca.2015.03.024. [Epub ahead of print]
INTRODUCTION: The oral neurokinin-1 antagonist aprepitant is recommended in several guidelines for preventing chemotherapy-induced nausea & vomiting (CINV) due to highly emetogenic cancer chemotherapy. Little is known about the feasibility and safety of aprepitant in patients treated with oxalip
PMID 25922233

Aprepitant and Fosaprepitant: A 10-Year Review of Efficacy and Safety.

Aapro M1, Carides A2, Rapoport BL2, Schmoll HJ2, Zhang L2, Warr D2.
The oncologist.Oncologist.2015 Apr;20(4):450-458. Epub 2015 Mar 20.
Chemotherapy-induced nausea and vomiting (CINV) is a common adverse event associated with anticancer treatment that can have a significant adverse impact on patient health-related quality of life and that can potentially undermine the effectiveness of chemotherapy. Traditional regimens to prevent CI
PMID 25795636

★リンクテーブル★

リンク元	「ホスアプレピタント」「フォサプレピタント・ジメグルミン」
関連記事	「dimeglumine」「fosaprepitant」

「ホスアプレピタント」

Fosaprepitant
Systematic (IUPAC) name
	[3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl] ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-5-oxo- 2H-1,2,4-triazol-1-yl]phosphonic acid
Clinical data
AHFS/Drugs.com	Multum Consumer Information
MedlinePlus	a604003
Licence data	EMA:Link, US FDA:link
Pregnancy; category	US: B (No risk in non-human studies);
Legal status	US: ℞-only;
Routes of; administration	Intravenous
Pharmacokinetic data
Bioavailability	n/a
Protein binding	>95% (aprepitant)
Metabolism	To aprepitant
Half-life	9 to 13 hours (aprepitant)
Identifiers
CAS Registry Number	172673-20-0 ; 265121-04-8 (dimeglumine)
ATC code	A04AD12
PubChem	CID: 219090
IUPHAR/BPS	7623
DrugBank	DB06717
UNII	6L8OF9XRDC
KEGG	D06597
ChEMBL	CHEMBL1199324
Chemical data
Formula	C23H22F7N4O6P
Molecular mass	614.406 g/mol
(what is this?) (verify)